Oncolytic Virotherapy
The Vaccinia virus stands out as one of the most versatile and powerful tools for oncolytic virotherapy. Its unique properties make it an ideal candidate for developing next-generation cancer treatments. Leveraging decades of safe use in humans and groundbreaking advancements in viral engineering, the Vaccinia virus is a conerstone of ReIGNITE's platform for oncolytic immunotherapy.
Engineered to travel through the blood, replicate throughout the tumor, and efficiently spread to sites of metastasis, helping to eliminate residual cancer cells that conventional therapies might miss.
Engineered with multiple immune-stimulatory transgenes, RIG-1250 is able to stimulate the immune system, helping facilitate a robust immune response against tumors
RIG-1250 can carry payloads up to ~50 kB, enabling the integration of multiple transgenes, regulatory control elements, and full length tissue-specific promotors.
Includes non-invasive imaging capabilities & off-switches for added safety.
RIG-1250 does not rely on a specific cell receptor and can thus infect and replicate within a broad range of cancer types.
Vaccinia has been utilized as a smallpox vaccine by the World Health Organization since 1976, with a proven track record of safe administration to billions of people.
Targeting Cancer
RIG-1250 is a next-generation oncolytic vaccinia virus therapeutic for IV delivery to tumors, providing efficient intra and inter-tumoral spread, cancer cell lysis and expression of complementary immunomodulatory transgenes for systemic anti-cancer immunity. Our platform utilizes both rational design and directed evolution technologies.
RIG-1250 has been engineered to selectively replicate in cancer cells, causing oncolysis, while sparing healthy cells.
RIG-1250 induces an immune responses to viral antigens and tumor antigens to target non-infected sites of cancer metastases.
Using directed evolution, RIG-1250 has been engineered to more efficient spread throughout the tumor and through the blood to sites of distant tumors.
Includes non-invasive imaging capabilities & off-switches for added safety.
RIG-1250 is engineered to achieve systemic spread through IV delivery, overcoming a critical challenge in cancer therapy.
